Ionis grants Recordati rights to zilganersen for Alexander disease
Pharmaceutical Technology
Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
pharminent
June 26, 2026 (Last updated: June 26, 2026)
Pharmaceutical Technology
Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.